None of pan-negative adenocarcinoma tumors available for further testing (N = 15) was positive for ROS1. The majority of KRAS mutations (single and multiple) were present in codon 12–81% (14/16), exclusively in adenocarcinoma tumors (16/16) and almost exclusively in Caucasians (12/16) (Supplementary Table 4). Here, ROS1 is linked to adenocarcinoma.